Reyataz Bristol Myers Squibb - Treatment for HIV Infection
Reyataz is a protease inhibitor (PI) used in combination with other antiretroviral agents for the treatment of HIV-1 infection.Posted: June 2003
Related articles
- Reyataz (atazanavir) label revised, adding dosing recommendations for pregnancy and postpartum period - February 7, 2011
- FDA Approves Labeling Update for Reyataz (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients - November 6, 2009
- U.S. Food & Drug Administration Approved the use of Reyataz (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients - October 2, 2008
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
